Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Parikh, Sameer A., Keating, Michael J., O'Brien, Susan, Wang, Xuemei, Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Estrov, Zeev, Badoux, Xavier, Lerner, Susan, Wierda, William G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081295/
https://ncbi.nlm.nih.gov/pubmed/21750315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-329177
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados